Company intelligence / Profile preview
Quanta Therapeutics
South San Francisco, California, United Statesquantatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Quanta Therapeutics is developing allosteric small molecules that target previously undruggable RAS mutations such as KRAS G12D and KRAS G12V. Their lead programs QTX3034, QTX3544, and QTX3046 are in Phase 1 clinical trials for advanced solid tumors. The company has presented preclinical and early clinical data at major oncology conferences and recently received IND clearance from the FDA for its lead asset[1][3][7].
- Therapeutic areas
- Oncology
- Modalities
- Small molecule drugSmall molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Quanta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quanta Therapeutics.